Four new SPMS patients not eligible for a Tiziana Life Sciences trial were dosed with foralumab nasal spray in an expanded access program.
All figures are in United States dollars unless otherwise stated. This news release contains forward-looking information that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback